Search

Your search keyword '"McCluggage, W. Glenn"' showing total 2,082 results
Start Over Author "McCluggage, W. Glenn"
2,082 results on '"McCluggage, W. Glenn"'

6. Unraveling the Molecular Landscape of Uterine Tumor Resembling Ovarian Sex Cord Tumor: Insights From A Clinicopathological, Morphologic, Immunohistochemical, and Molecular Analysis of 35 Cases

Author

Flídrová, Miroslava, Hájková, Nikola, Hojný, Jan, Dvořák, Jiří, Michálková, Romana, Krkavcová, Eva, Laco, Jan, McCluggage, W. Glenn, Giordano, Giovanna, Silini, Enrico Maria, Michalová, Květoslava, Bizoń, Magdalena, Němejcová, Kristýna, Dundr, Pavel, and Kendall Bártů, Michaela

Published
2024
Full Text
View/download PDF

11. Classifying Anal Intraepithelial Neoplasia 2 Based on LAST Recommendations.

Author

Liu, Yuxin, McCluggage, W Glenn, Darragh, Teresa M, Zheng, Wenxin, Roberts, Jennifer M, Park, Kay J, Hui, Pei, Blakely, Morgan, Sigel, Keith, and Gaisa, Michael M

Subjects
Cancer, Anus Neoplasms, Biomarkers, Tumor, Biopsy, Cyclin-Dependent Kinase Inhibitor p16, Female, Humans, Papillomaviridae, Papillomavirus Infections, Squamous Intraepithelial Lesions, Uterine Cervical Neoplasms, Interobserver agreement, Human papillomavirus, Anal intraepithelial neoplasia 2, p16 Immunohistochemistry, Medical and Health Sciences, Pathology
Abstract

ObjectivesThe Lower Anogenital Squamous Terminology (LAST) recommendations classify human papillomavirus-associated squamous lesions into low- and high-grade squamous intraepithelial lesions (LSILs/HSILs). Our study aimed to assess interobserver agreement among 6 experienced pathologists in assigning 40 anal lesions previously diagnosed as anal intraepithelial neoplasia 2 (AIN 2) to either HSIL or non-HSIL categories.MethodsAgreement based on photomicrographs of H&E alone or H&E plus p16 immunohistochemistry was calculated using κ coefficients.ResultsAgreement was fair based on H&E alone (κ = 0.42; 95% confidence interval [CI], 0.34-0.52). Adding p16 improved agreement to moderate (κ = 0.55; 95% CI, 0.54-0.62). On final diagnosis, 21 cases (53%) had unanimous diagnoses, and 19 (47%) were divided. When designating p16 results as positive or negative, agreement was excellent (κ = 0.92; 95% CI, 0.83-0.95). Among variables (staining location, extent, and intensity), staining of the basal/parabasal layers was a consistent feature in cases with consensus for positive results (20/20). Of the 67 H&E diagnoses with conflicting p16 results, participants modified 32 (48%), downgrading 23 HSILs and upgrading 9 non-HSILs.ConclusionsAlthough p16 increased interobserver agreement, disagreement remained considerable regarding intermediate lesions. p16 expression, particularly if negative, can reduce unwarranted HSIL diagnoses and unnecessary treatment.

Published
2021

13. Refined criteria for p53 expression in ovarian mucinous tumours are highly concordant with TP53 mutation status, but p53 expression/TP53 status lack prognostic significance

Author

Dundr, Pavel, Hájková, Nikola, Kendall Bártů, Michaela, Cibula, David, Drozenová, Jana, Fabian, Pavel, Fadare, Oluwole, Frühauf, Filip, Hausnerová, Jitka, Hojný, Jan, Laco, Jan, Lax, Sigurd F., Matěj, Radoslav, Méhes, Gábor, Michálková, Romana, Němejcová, Kristýna, Singh, Naveena, Stolnicu, Simona, Švajdler, Marián, Zima, Tomáš, McCluggage, W. Glenn, and Stružinská, Ivana

Published
2023
Full Text
View/download PDF

14. A comprehensive immunohistochemical analysis of IMP2 and IMP3 in 542 cases of ovarian tumors

Author

Němejcová, Kristýna, Bártů, Michaela Kendall, Michálková, Romana, Drozenová, Jana, Fabian, Pavel, Fadare, Oluwole, Hausnerová, Jitka, Laco, Jan, Matěj, Radoslav, Méhes, Gábor, Singh, Naveena, Stolnicu, Simona, Škapa, Petr, Švajdler, Marián, Stružinská, Ivana, Cibula, David, Kocian, Roman, Lax, Sigurd F., McCluggage, W. Glenn, and Dundr, Pavel

Published
2023
Full Text
View/download PDF

18. High-Grade Endometrial Stromal Sarcomas With YWHAE::NUTM2 Gene Fusion Exhibit Recurrent CDKN2A Alterations and Absence of p16 Staining is a Poor Prognostic Marker

Author

Kommoss, Felix K.F., Mar, Lisa-Marie, Howitt, Brooke E., Hanley, Krisztina, Turashvilli, Gulisa, Buslei, Rolf, Irving, Julie A., Dickson, Brendan C., Koelsche, Christian, Sinn, Hans-Peter, Schirmacher, Peter, von Deimling, Andreas, Chiang, Sarah, McCluggage, W. Glenn, Croce, Sabrina, Stewart, Colin J.R., and Lee, Cheng-Han

Published
2023
Full Text
View/download PDF

19. Primary Mucinous Tumors of the Ovary: An Interobserver Reproducibility and Detailed Molecular Study Reveals Significant Overlap Between Diagnostic Categories

Author

Dundr, Pavel, Bártů, Michaela, Bosse, Tjalling, Bui, Quang Hiep, Cibula, David, Drozenová, Jana, Fabian, Pavel, Fadare, Oluwole, Hausnerová, Jitka, Hojný, Jan, Hájková, Nikola, Jakša, Radek, Laco, Jan, Lax, Sigurd F., Matěj, Radoslav, Méhes, Gábor, Michálková, Romana, Šafanda, Adam, Němejcová, Kristýna, Singh, Naveena, Stolnicu, Simona, Švajdler, Marián, Zima, Tomáš, Stružinská, Ivana, and McCluggage, W. Glenn

Published
2023
Full Text
View/download PDF

22. The cytokeratin 17 expression in primary ovarian tumors has diagnostic but not prognostic significance

Author

Dundr, Pavel, Bazalová, Barbora, Bártů, Michaela, Bosse, Tjalling, Drozenová, Jana, Fabian, Pavel, Fadare, Oluwole, Hausnerová, Jitka, Jakša, Radek, Laco, Jan, Lax, Sigurd F., Matěj, Radoslav, McCluggage, W. Glenn, Méhes, Gábor, Michálková, Romana, Němejcová, Kristýna, Singh, Naveena, Stolnicu, Simona, Škapa, Petr, Švajdler, Marián, and Stružinská, Ivana

Published
2022
Full Text
View/download PDF

23. Practical guidance for assessing and reporting lymphovascular space invasion (LVSI) in endometrial carcinoma.

Author

Peters, Elke E M, Nucci, Marisa R, Gilks, C Blake, McCluggage, W Glenn, and Bosse, Tjalling

Subjects
ENDOMETRIAL cancer, CANCER relapse, PROGNOSIS, INTERNATIONAL organization, LYMPH nodes
Abstract

Lymphovascular space invasion (LVSI) is an important prognostic parameter in endometrial carcinoma (EC) and has gained increasing interest in recent years due to an expanding body of evidence of its independent prognostic value, especially when the presence of LVSI is quantified. A key strength of LVSI as a prognostic factor is that it can be detected on routine microscopic examination, without ancillary tests, and thus can be used in low‐resource settings. A weakness, however, is the lack of uniformly applied criteria for assessment and quantification of LVSI, resulting in interobserver variation in diagnosis. This is confounded by artefacts and other morphological features that may mimic LVSI (commonly referred to as pseudo‐LVSI). Despite these issues, multiple studies have shown that LVSI is strongly associated with lymph node (LN) metastasis and is an independent risk factor for LN recurrence and distant metastasis. Consequently, the presence of substantial/extensive LVSI has become an important consideration in formulating adjuvant treatment recommendations in patients with EC, and this has been incorporated in the recent International Federation of Gynecology and Obstetrics (FIGO) 2023 staging system. Herein, we review the current literature on LVSI in EC and discuss its role as a prognostic marker, the reproducibility of LVSI assessment and distinction between LVSI and its mimics. We provide illustrations of key diagnostic features and discuss the two‐tiered (none/focal versus substantial) system of LVSI classification. This work is intended to provide guidance to practising pathologists and unify the approach towards LVSI assessment in EC. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

33. Ovarian Sex Cord-Stromal Neoplasms: An Overview of Molecular Events and How to Correlate Morphology With Molecular Findings

Author

Rabban, Joseph T. and McCluggage, W. Glenn

Abstract

Since the discovery in 2009 that missence pathogenic variants/mutations in FOXL2are extremely common in ovarian adult granulosa cell tumours, the last 2 decades have witnessed significant developments in our understanding of the molecular events underlying the pathogenesis of other ovarian sex cord-stromal tumours (SCSTs). In this review, we cover the molecular events in ovarian SCSTs and provide practical guidance to the reporting pathologist as to how and when molecular testing may be useful in diagnosis. We stress the need to correlate the morphology and molecular since most of the molecular events are not entirely specific for a particular tumour type and our knowledge is continually evolving with the elucidation of “new” molecular events. We also discuss that in some tumours, molecular testing is helpful in triaging the patient for genetic referral and germline testing since some of the molecular events may be germline in nature.

Published
2025
Full Text
View/download PDF

39. Preventing Ovarian Cancer through early Excision of Tubes and late Ovarian Removal (PROTECTOR): protocol for a prospective non-randomised multi-center trial

Author

Gaba, Faiza, Robbani, Sadiyah, Singh, Naveena, McCluggage, W Glenn, Wilkinson, Nafisa, Ganesan, Raji, Bryson, Gareth, Rowlands, Gareth, Tyson, Charlotte, Arora, Rupali, Saridogan, Ertan, Hanson, Helen, Burnell, Matthew, Legood, Rosa, Evans, D Gareth, Menon, Usha, Manchanda, Ranjit, Snape, Katie, Ghaem-Maghami, Sadaf, Mehra, Gautam, Brady, Angela, Rosenthal, Adam, MacKintosh, Michelle, Harley, Ian, Sundar, Sudha, Newton, Claire, Devaja, Omer, Duncan, Tim, Chattopadhyay, Supratik, Povolotskaya, Natalia, Iyer, Rema, Side, Lucy, Tailor, Anil, Seters, Manon van, Kodiathodi, Suma, Sengupta, Partha, Cameron, Iain, Kaushik, Sonali, Williamson, Karin, Edey, Katherine, Taylor, Sian, Phillips, Andrew, Willett, Mark, Chalhoub, Tony, Rao, Sanjay, Matthews, Nicholas, Sharma, Aarti, Fegan, Scott, Gurumurthy, Mahalakshmi, Ragupathy, Kalpana, Abdul, Beena, Hamoodi, Ibraheem, Park, Claire, Borley, Jane, Hutson, Richard, Lutchman-Singh, Kerryn, and Peevor, Richard

Published
2021
Full Text
View/download PDF

41. SOX17 expression in mesonephric‐like adenocarcinomas and mesonephric remnants/hyperplasia of the female genital tract: Expanding its utility as a Müllerian biomarker.

Author

Zhang, Xiaoming, McCluggage, W. Glenn, Howitt, Brooke E, and Hirsch, Michelle S

Subjects
*GENITALIA, *ENDOMETRIAL cancer, *BIOMARKERS, *ADENOCARCINOMA, *HISTOGENESIS
Abstract

Aims: Recently, SOX17 has emerged as a promising biomarker for non‐mucinous Müllerian (ovarian and endometrial) carcinomas, demonstrating increased specificity in comparison to PAX8 while maintaining similar sensitivity. However, expression of SOX17 in mesonephric‐like adenocarcinoma (MLA), a carcinoma of the female genital tract with uncertain, but probably Müllerian histogenesis, remains unexplored. This study aims to address this gap. Methods and results: SOX17 immunohistochemistry was performed on whole tissue sections from 68 MLAs originating from the endometrium or ovary and seven cervical mesonephric carcinomas, as well as six mesonephric remnants/hyperplasias. Using a four‐tiered scoring system based on distribution and intensity of staining, 68% of MLA displayed a negative/low (< 10%) SOX17 expression pattern, which contrasts with the high expression observed in most Müllerian carcinomas. However, 22% of MLA demonstrated high SOX17 expression, similar to other endometrial and ovarian carcinomas. Similarly, five of seven (72%) mesonephric carcinomas of the cervix were SOX17‐negative, but two cases (28%) were positive. All mesonephric remnants/hyperplasias were SOX17 negative. Conclusions: The majority of MLA are negative or exhibit low SOX17 expression, in contrast to the diffuse and strong expression commonly seen in other types of Müllerian carcinoma. However, a subset of MLAs demonstrate high SOX17 expression. Therefore, absence of SOX17 staining is supportive for MLA when the differential includes another non‐mucinous Müllerian carcinoma. SOX17 may also be useful for differentiating mesonephric remnants/hyperplasias from Müllerian malignancies and benign Müllerian glandular lesions. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

42. STK11 (LKB1) immunohistochemistry is a sensitive and specific marker for STK11 adnexal tumours.

Author

Dehghani, Amir, Sharma, Aarti E, Siegmund, Stephanie E, Carreon, Chrystalle K, Stewart, Colin J R, Medeiros, Fabiola, Mirkovic, Jelena, Nucci, Marisa R, Crum, Christopher P, Hornick, Jason L, Howitt, Brooke E, McCluggage, W Glenn, and Kolin, David L

Subjects
MUCINOUS adenocarcinoma, GRANULOSA cells, SERTOLI cells, LEYDIG cells, ELECTRONIC publications, FALLOPIAN tubes
Abstract

Aims: STK11 adnexal tumour is a rare, recently described malignant neoplasm that is associated with Peutz–Jeghers syndrome. [Correction added on 3 October 2024, after first online publication: 'ST11' in preceding sentence has been corrected to 'STK11' in this version.] It predominantly originates from the para‐adnexal soft tissues and often shows secondary involvement of the fallopian tube and ovary. STK11 adnexal tumours have a broad differential diagnosis due to their variable morphology and non‐specific immunoprofile, and diagnostic confirmation currently requires sequencing to identify an STK11 mutation. We investigate the diagnostic utility of STK11 (LKB1) immunohistochemistry (IHC) in a cohort of STK11 adnexal tumours and morphological mimics. Methods and results: IHC for STK11 was performed on 122 tumours, including 17 STK11 adnexal tumours and 105 morphological mimics (10 female adnexal tumours of Wolffian origin, 22 adult granulosa cell tumours, 10 juvenile granulosa cell tumours, four Sertoli–Leydig cell tumours, two Leydig cell tumours, one Sertoli cell tumour, one steroid cell tumour, four extra‐ovarian sex cord‐stromal tumours, 16 ovarian endometrioid carcinomas, eight tubo‐ovarian high‐grade serous carcinomas, five ovarian mesonephric‐like adenocarcinomas, 14 ovarian carcinosarcomas, five peritoneal malignant mesotheliomas, two pelvic plexiform leiomyomata and one ovarian solid pseudopapillary tumour). All STK11 adnexal tumours showed complete loss of cytoplasmic staining for STK11. All other tumour types showed retained cytoplasmic staining, except for one endometrioid carcinoma with mucinous differentiation which showed complete loss of STK11 expression and a high‐grade serous carcinoma with subclonal loss. Conclusions: STK11 is a highly sensitive and specific immunohistochemical marker for distinguishing STK11 adnexal tumour from its histological mimics, and can obviate the need for confirmatory molecular studies in the appropriate morphological context. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

44. High-grade transformation of low-grade endometrial stromal sarcomas lacking YWHAE and BCOR genetic abnormalities

Author

Zou, Youran, Turashvili, Gulisa, Soslow, Robert A., Park, Kay J., Croce, Sabrina, McCluggage, W. Glenn, Stewart, Colin J.R., Oda, Yoshinao, Oliva, Esther, Young, Robert H., Da Cruz Paula, Arnaud, Dessources, Kimberly, Ashley, Charles W., Hensley, Martee L., Yip, Stephen, Weigelt, Britta, Benayed, Ryma, Antonescu, Cristina R., Lee, Cheng-Han, and Chiang, Sarah

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results